Yilin Zhang

发表

Management of cytokine release syndrome related to CAR-T cell therapy

B. Lei, Wanggang Zhang, Liu-fang Gu, 2019, Frontiers of Medicine.

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

B. Lei, Wanggang Zhang, Liu-fang Gu, 2017 .

High programmed death 1 expression on T cells in aplastic anemia.

Juan Yang, Wanggang Zhang, A. He, 2017, Immunology letters.

Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

Saijuan Chen, Hua Jiang, Jian-yong Li, 2022, Journal of Hematology & Oncology.

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

B. Lei, Y. Geng, Zong-fang Li, 2018, Journal of Hematology & Oncology.

Horse versus rabbit antithymocyte globulin in immunosuppressive therapy of treatment-naïve aplastic anemia: a systematic review and meta-analysis

Huan Yao, Wanggang Zhang, Xiao-rong Ma, 2017, Annals of Hematology.

Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China

B. Lei, Liu-fang Gu, Fangxia Wang, 2020 .

Updated Analysis of a Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed Against B-Cell Maturation Antigen, in Patients with Relapsed/Refractory Multiple Myeloma

Zong-fang Li, B. Lei, Y. Geng, 2018, Blood.

Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.

A. He, Jie Liu, Baiyan Wang, 2023, Current research in translational medicine.

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

B. Lei, Y. Geng, Zong-fang Li, 2019, Blood.

Effects of CpG oligodeoxynucleotides on the differentiation of Treg/Th17 cells.

B. Lei, Yuqiang Ji, Wanggang Zhang, 2021, Molecular immunology.

Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report

Liu-fang Gu, Fangxia Wang, Xing-mei Cao, 2022, Journal of Medical Case Reports.